Abstract
Purpose
To assess the prognostic significance of sarcomatoid differentiation for surgically treated metastatic renal cell carcinoma (mRCC).
Methods
Patients undergoing cytoreductive nephrectomy for mRCC in our center between 2006 and 2014 were included. All enrolled patients were separated into two groups according to the presence of sarcomatoid differentiation. Clinical and pathological variables were recorded. Student’s t test or Chi-square test was applied to compare them. Univariate and multivariate Cox regression were performed to determine independent prognostic factors for oncologic outcomes.
Results
Of the 184 patients with mRCC included, 27 (14.7%) patients presented with sarcomatoid differentiation. The presence of sarcomatoid differentiation was associated with higher rates of non-clear cell histology (P = 0.009), higher Fuhrman grade (P < 0.001), higher rates of presenting tumor necrosis (P = 0.005), worse IMDC risk group (P = 0.022), and MSKCC risk group (P = 0.020). Patients with sarcomatoid differentiation showed shorter median progression-free survival and overall survival. Multivariate analysis identified that sarcomatoid differentiation was independently associated with progression-free survival (hazard ratio [HR]: 2.002, 95% CI 1.047–3.828; P = 0.036) and overall survival (HR: 1.922, 95% CI 1.073–3.445; P = 0.028). Sarcomatoid differentiation remained to be independently associated with inferior PFS (HR: 2.097, 95% CI 1.091–4.030; P = 0.026) and OS (HR: 2.245, 95% CI 1.276–3.951; P = 0.005) for clear cell mRCC.
Conclusion
The presence of sarcomatoid differentiation is independently associated with poor oncologic outcomes for surgically treated mRCC patients. The association remains significant when the subject of study is restricted to clear cell mRCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bex A, Ljungberg B, van Poppel H, Powles T (2016) The role of cytoreductive nephrectomy: European Association of Urology Recommendations in 2016 European urology. doi:10.1016/j.eururo.2016.07.005
Bi M et al (2016) Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci USA 113:2170–2175. doi:10.1073/pnas.1525735113
Brookman-May S et al (2013) Prognostic effect of sarcomatoid dedifferentiation in patients with surgically treated renal cell carcinoma: a matched-pair analysis. Clin Genitourin Cancer 11:465–470. doi:10.1016/j.clgc.2013.04.026
Chen L et al (2016) Invasion of the urinary collecting system is an independent prognostic factor in pT3 renal cell carcinoma. Urol Oncol. doi:10.1016/j.urolonc.2016.02.019
Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435–441
de Peralta-Venturina M et al (2001) Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25:275–284
Delahunt B et al (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504. doi:10.1097/PAS.0b013e318299f0fb
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474. doi:10.1245/s10434-010-0985-4
Farrow GM, Harrison EG Jr, Utz DC (1968) Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. 3. Cancer 22:556–563
Golshayan AR et al (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 27:235–241. doi:10.1200/jco.2008.18.0000
Gu L et al (2016) Prognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram. Sci Rep 6:23846. doi:10.1038/srep23846
Haas NB et al (2012) A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol (Northwood, London, England) 29:761–767. doi:10.1007/s12032-011-9829-8
Heng DY et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148. doi:10.1016/s1470-2045(12)70559-4
Ito T et al (2015) Genomic copy number alterations in renal cell carcinoma with sarcomatoid features. J Urol. doi:10.1016/j.juro.2015.10.180
Kanamaru H, Sasaki M, Miwa Y, Akino H, Okada K (1999) Prognostic value of sarcomatoid histology and volume-weighted mean nuclear volume in renal cell carcinoma. BJU Int 83:222–226
Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP, Koppie TM (2012) Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 188:391–397. doi:10.1016/j.juro.2012.04.006
Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC, Ku JH (2007) Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 95:317–323. doi:10.1002/jso.20669
Kyriakopoulos CE et al (2015) Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 13:e79–e85. doi:10.1016/j.clgc.2014.08.011
Malouf GG et al (2016) Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. Eur Urol. doi:10.1016/j.eururo.2016.01.051
Merrill MM et al (2015) Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: natural history and outcomes after surgical resection with curative intent. Urol Oncol. doi:10.1016/j.urolonc.2014.11.021
Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL (2002) Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167:65–70
Molina AM et al (2011) Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 34:454–459. doi:10.1097/COC.0b013e3181f47aa4
Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463. doi:10.1200/JCO.2004.06.132
Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP (2004) Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101:1545–1551. doi:10.1002/cncr.20541
Shuch B, Bratslavsky G, Linehan WM, Srinivasan R (2012a) Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist 17:46–54. doi:10.1634/theoncologist.2011-0227
Shuch B et al (2012b) Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int 109:1600–1606. doi:10.1111/j.1464-410X.2011.10785.x
Voss MH et al (2014) Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol 25:663–668. doi:10.1093/annonc/mdt578
Acknowledgements
The study was supported by the National High Technology Research and Development Program (“863” Program) of China, China (2014AA020607).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
We declare that we have no conflict of interest.
Ethical approval
For this type of study, formal consent is not required.
Additional information
These authors L. Gu, H. Li and H. Wang equally dedicated to this article.
Rights and permissions
About this article
Cite this article
Gu, L., Li, H., Wang, H. et al. Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma. J Cancer Res Clin Oncol 143, 499–508 (2017). https://doi.org/10.1007/s00432-016-2304-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2304-3